TrialThe lancet. Gastroenterology & hepatology2018
Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.
Richard Adams et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
35 papers cite it
this paperpooled ittrialcites it